Guest Editorial: Petri Dish to Operatory: Bridging the Gap

Wathen, William F.

doi:10.1177/00220345900690021701

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The CR samples showed a pre-activated immune microenvironment at baseline, substantiated by the enrichment of genes related to antigen processing and a proportional enrichment of T cells, NKCD56 bright cells and macrophages. Macrophages have often been shown to be a negative prognostic factor, although M1 macrophages, which sustain anti-tumor immune response, have been associated with favorable prognosis 39,40 . However, coordinated activation of the cytotoxic response was observed only after treatment, suggesting that despite a permissive microenvironment observed at baseline, tumor destruction in responding lesions requires a strong switch from chronic to acute inflammation, which is captured by the ICR genes.…”

Section: Discussionmentioning

confidence: 99%

Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod

Rozenblit

Hendrickx

Heguy

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Imiquimod is a topical toll-like-receptor-7 agonist currently used for treating basal cell carcinoma. Recently, imiquimod has demonstrated tumor regression in melanoma and breast cancer skin metastases. However, the molecular perturbations induced by imiquimod in breast cancer metastases have not been previously characterized. Here, we describe transcriptomic profiles associated with responsiveness to imiquimod in breast cancer skin metastases. Baseline and post-treatment tumor samples from patients treated with imiquimod in a clinical trial were profiled using Nanostring technology. Through an integrative analytic pipeline, we showed that tumors from patients who achieved a durable clinical response displayed a permissive microenvironment, substantiated by the upregulation of transcripts encoding for molecules involved in leukocyte adhesion and migration, cytotoxic functions, and antigen presentation. In responding patients, Imiquimod triggered a strong T-helper-1 (Th-1)/cytotoxic immune response, characterized by the coordinated upregulation of Th-1 chemokines, migration of Th-1 and cytotoxic T cells into the tumor, and activation of immune-effector functions, ultimately mediating tumor destruction. In conclusion, we have shown that topical imiquimod can induce a robust immune response in breast cancer metastases, and this response is more likely to occur in tumors with a pre-activated microenvironment. In this setting, imiquimod could be utilized in combination with other targeted immunotherapies to increase therapeutic efficacy.

show abstract

Section: Discussionmentioning

confidence: 99%

Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod

Rozenblit

Hendrickx

Heguy

et al. 2019

Sci Rep

View full text Add to dashboard Cite

show abstract

Publication of Research: The Ethical Dimension

Lynch

1994

J Dent Res

View full text Add to dashboard Cite

If science is to achieve its goal, i.e., advancement of human well-being, the results of scientific research must be made available. When such results are presented, that presentation must be 'ethical'; it must conform to recognized standards of honesty, originality, and fairness. Unfortunately, not all such presentations conform to these standards; the public and scientific community alike are becoming ever more concerned about duplication in publication, about illegitimate claims to authorship, and about misleading use of statistics in presentation of experimental results. Certain of these 'unethical' practices can be eliminated or minimized by education, institutional practice, and requirements set by scientific journals. In the end, however, 'ethical publication' will depend on the 'ethical investigator'--an individual who has professed dedication to truth and the well-being of mankind.

show abstract

Guest Editorial: Petri Dish to Operatory: Bridging the Gap

Cited by 2 publications

References 0 publications

Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod

Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod

Publication of Research: The Ethical Dimension

Contact Info

Product

Resources

About